Metabolic syndrome
Conditions
Interventions
Experimental group:Conventional basic treatment
Experimental group:Abdominal tuina
Experimental group:Acupoint tuina
Control group :Conventional basic treatment
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1)Aged 18 to 65 years (including borders), no gender limitation. (2)Participants who meet the metabolic syndrome diagnostic criteria identified by International Diabetes Federation. (3)Traditional Chinese medicine syndrome was heat stagnation of liver and stomach (4)Participants have fasting blood glucose between 5.6 and 7.0 mmol/L, and/or 2h post-load glucose level less than 11.1 mmol/L. And no antidiabetic drugs are used to control the blood glucose level at present. (5)Participants have triglyceride between 1.7 and 5.6 mmol/L,high density lipoprotein cholesterol less than 1.03 mmol/L (male) and 1.29 mmol/L (female), total cholesterol less than 6.2 mmol/L and low density lipoprotein cholesterol less than 4.1 mmol/L. And no lipid-regulating drugs are used to control the blood lipid level at present. (6)The blood pressure range of the participants are 140-159/90-99 mmHg, cardiovascular risk level stratified into low-risk, and no antihypertensive drugs are used to control the blood pressure at present. (7)Sign the informed consent by the participants.
Exclusion criteria
Exclusion criteria: (1)Other primary diseases including chronic kidney disease, chronic liver disease and hypothyroidism lead to abnormalities in blood glucose, blood lipids and blood pressure. (2)Combined with severe cardiovascular and cerebrovascular diseases, such as heart failure, severe hypertension, cerebral hemorrhage, etc. (3)Combined with severe liver dysfunction (ALT or AST more than 3 times the upper limit of normal value), malignant tumors and autoimmune diseases. (4)Pregnancy, preparing for pregnancy or breastfeeding women. (5)Allergic constitution. (6)Those who are participating in other clinical trials or have participated in other drug clinical trials within one month after the end. (7)The researcher judges that it is not suitable to enter the research due to other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abdominal circumference; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2 hours postprandial blood glucose;ApoA1;ApoB;Lp(a);Clinic diastolic blood pressure;HDL-C;Fasting blood glucose;HOMA-IR;TCM Evidence Score;N-HDL-C;TG;Clinic systolic blood pressure;CRP;IL-18;leptin;adiponectin;TNF-a;Fasting serum insulin;omentin;TC;IL-1ß;chemerin;LDL-C;Mean arterial pressure; | — |
Countries
China
Contacts
Public ContactZhangBingxuan
Guang'anmen Hospital,China Academy of Chinese Medical Sciences
Outcome results
None listed